A UPLC-MS/MS method for therapeutic drug monitoring of etonogestrel

Therapeutic Drug Monitoring

Volumn 35, Issue 6, 2013, Pages 844-848

  Thomas, Tiffany ^a   Petrie, Kelsey ^a   Shim, Joonho ^b   Abildskov, Kirsten M ^a   Westhoff, Carolyn L ^a   Cremers, Serge ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Inha University School of Medicine   (South Korea)

Author keywords

Contraception; Etonogestrel; LC MS MS; Pharmacokinetics; Vaginal ring

Indexed keywords

D 8PROGESTERONE; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETONOGESTREL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CALIBRATION; CASE REPORT; CONTROLLED STUDY; DRUG MONITORING; DRUG RAPID TEST; DRUG STABILITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IONIZATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; PATIENT CARE; PRIORITY JOURNAL; SIGNAL NOISE RATIO; STEADY STATE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VAGINA RING;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DRUG MONITORING; FEMALE; HUMANS; LIMIT OF DETECTION; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84889248522     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31829a10fa     Document Type: Article

References (16)

1. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100:585-593. (Pubitemid 35246150)
2. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233-242.
3. van den Heuvel MW, van Bragt AJ, Alnabawy AK, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168-174. (Pubitemid 41133355)
4. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception. 2010;82:314-323.
5. Mishell DR Jr, Talas M, Parlow AF, et al. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol. 1970;107:100-107.
6. Kerns J, Darney P. Vaginal ring contraception. Contraception. 2011;83: 107-115.
7. Oddsson K, Leifels-Fischer B, de Melo NR, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception. 2005;71:176-182. (Pubitemid 40250198)
8. Roumen FJ, Apter D, Mulders TM, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16:469-475. (Pubitemid 32218795)
9. Townsend JW, Sitruk-Ware R, Williams K, et al. New strategies for providing hormonal contraception in developing countries. Contraception. 2011;83:405-409.
10. Fu H, Darroch JE, Haas T, et al. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect. 1999;31:56-63. (Pubitemid 29202636)
11. Boyd RA, Zegarac EA, Eldon MA. The effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy. J Clin Pharmacol. 2003;43:52-58. (Pubitemid 36015443)
12. Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol. 2002;99(pt 1):820-827. (Pubitemid 34442461)
13. Holt VL, Scholes D, Wicklund KG, et al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol. 2005;105:46-52. (Pubitemid 40189910)
14. Bennink HJ. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000;5(suppl 2):12-20. (Pubitemid 32171233)
15. Moser C, Zoderer D, Luef G, et al. Simultaneous online SPE-LC-MS/MS quantification of six widely used synthetic progestins in human plasma. Anal Bioanal Chem. 2012;403:961-972.
16. Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol. 2012;207:39.e1-39.e6.